Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
06/28/2023 | IMMUNIC, INC. | VTL | Grant | Stock Option | 16k | $1.94 | $31k | | 06/28/2023 |
01/03/2023 | Cue Biopharma, Inc. | CUE | Grant | Stock Option (right to buy) | 10k | $2.66 | $26.6k | | 01/03/2023 |
07/05/2022 | MEI Pharma, Inc. | MEIP | Grant | Stock Option (Right to Buy) | 87.5k | $0.54 | $47.2k | | 07/05/2022 |
06/15/2022 | IMMUNIC, INC. | VTL | Grant | Stock Option | 10k | $3.40 | $34k | | 06/15/2022 |
01/03/2022 | Cue Biopharma, Inc. | CUE | Grant | Stock Option (right to buy) | 10k | $12.28 | $122.8k | | 01/03/2022 |
07/01/2021 | MEI Pharma, Inc. | MEIP | Grant | Stock Option (Right to Buy) | 50k | $2.95 | $147.5k | | 07/01/2021 |
06/10/2021 | IMMUNIC, INC. | VTL | Grant | Stock Option | 10k | $14.77 | $147.7k | | 06/10/2021 |
01/04/2021 | Cue Biopharma, Inc. | CUE | Grant | Stock Option (right to buy) | 10k | $12.36 | $123.6k | | 01/04/2021 |
09/17/2020 | Cue Biopharma, Inc. | CUE | Grant | Stock Option (right to buy) | 50k | $17.21 | $860.5k | | 09/17/2020 |
07/02/2020 | MEI Pharma, Inc. | MEIP | Grant | Stock Option (Right to Buy) | 50k | $3.49 | $174.5k | | 07/02/2020 |
07/02/2020 | IMMUNIC, INC. | VTL | Grant | Stock Option | 15k | $12.30 | $184.5k | | 07/02/2020 |
10/11/2019 | IMMUNIC, INC. | VTL | Grant | Stock Option | 30k | $9.54 | $285.8k | | 10/11/2019 |
07/01/2019 | MEI Pharma, Inc. | MEIP | Grant | Stock Option (Right to Buy) | 60k | $2.52 | $151.2k | | 07/01/2019 |
07/26/2018 | ORGANOVO HOLDINGS, INC. | ONVO | Grant | Stock Option (Right to Buy) | 45.5k | $1.29 | $58.7k | | 07/26/2018 |
08/24/2017 | ORGANOVO HOLDINGS, INC. | ONVO | Grant | Stock Option (Right to Buy) | 42.5k | $1.97 | $83.7k | | 08/24/2017 |
04/10/2017 | Hepion Pharmaceuticals, Inc. | CTRV | Grant | Stock Options | 35k | $1.60 | $56k | | 04/10/2017 |
08/17/2016 | ORGANOVO HOLDINGS, INC. | ONVO | Grant | | 7.5k | $0.00 | $0 | | 08/17/2016 |
08/17/2016 | ORGANOVO HOLDINGS, INC. | ONVO | Grant | | 18.5k | $4.35 | $80.5k | | 08/17/2016 |
08/20/2015 | ORGANOVO HOLDINGS, INC. | ONVO | Grant | Stock Option (Right to Buy) | 37k | $2.09 | $77.3k | | 08/20/2015 |
03/17/2015 | Allergan plc | AGN | Payment of Exercise | Ordinary Shares, par value $0.0001 | 549 | $307.51 | $168.8k | | 03/17/2015 |
08/20/2014 | ORGANOVO HOLDINGS, INC. | ONVO | Grant | Stock Option (Right to Buy) | 31.5k | $7.62 | $240k | | 08/20/2014 |
05/09/2014 | Allergan plc | AGN | Grant | Ordinary Shares, par value $0.0001 | 1.1k | $197.05 | $225k | | 05/09/2014 |
11/06/2013 | Allergan plc | AGN | Sale | Ordinary Shares | 300 | $157.34 | $47.2k | | 11/06/2013 |
10/01/2013 | Allergan plc | AGN | Grant | Ordinary Shares | 1.2k | $0.00 | $0 | | 10/01/2013 |
08/21/2013 | ORGANOVO HOLDINGS, INC. | ONVO | Grant | Stock Option (Right to Buy) | 30.5k | $5.86 | $178.7k | | 08/21/2013 |
06/05/2013 | ORGANOVO HOLDINGS, INC. | ONVO | Grant | Stock Option (Right to Buy) | 45.5k | $3.98 | $181.1k | | 06/05/2013 |
07/01/2012 | Oncotelic Therapeutics, Inc. | MATN | Grant | Stock Option (Right to Buy) | 25.2k | $0.55 | $13.9k | | 07/01/2012 |
07/01/2012 | Oncotelic Therapeutics, Inc. | MATN | Grant | Common Stock, $0.01 par value per share | 18.1k | $0.00 | $0 | | 07/01/2012 |
06/07/2012 | IDENIX PHARMACEUTICALS INC | IDIX | Grant | Stock Option (Right to Buy) | 20k | $9.03 | $180.6k | | 06/07/2012 |
10/31/2011 | Oncotelic Therapeutics, Inc. | MATN | Grant | Common Stock, $0.01 par value per share | 6.1k | $0.00 | $0 | | 10/31/2011 |
10/31/2011 | Oncotelic Therapeutics, Inc. | MATN | Grant | Stock Option (Right to Buy) | 8.6k | $1.65 | $14.2k | | 10/31/2011 |
09/23/2010 | SOLIGENIX, INC. | SNGX | Grant | | 300k | $0.21 | $61.5k | | 09/23/2010 |
03/30/2010 | IDENIX PHARMACEUTICALS INC | IDIX | Grant | Stock Option (Right to Buy) | 3.3k | $2.79 | $9.3k | | 03/30/2010 |
03/30/2010 | IDENIX PHARMACEUTICALS INC | IDIX | Grant | Stock Option (Right to Buy) | 15k | $2.79 | $41.8k | | 03/30/2010 |
03/30/2010 | IDENIX PHARMACEUTICALS INC | IDIX | Grant | Employee Stock Option (Right to Buy) | 15k | $2.79 | $41.8k | | 03/30/2010 |
|